Acrivon Therapeutics, Inc. Common StockACRVNASDAQ
Loading
R&D Expenses Over TimeStrong
Percentile Rank80
3Y CAGR+35.8%
5Y CAGR+100.1%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+35.8%/yr
Annual compound
5Y CAGR
+100.1%/yr
Recent deceleration
Percentile
P80
Within normal range
vs 5Y Ago
32.1x
Strong expansion
Streak
1 yr
Consecutive declineStrong
PeriodValueYoY Change
2025$59.99M-6.3%
2024$63.99M+40.7%
2023$45.49M+89.9%
2022$23.95M+74.6%
2021$13.72M+633.6%
2020$1.87M-